LPL Financial’s Sagimet Biosciences SGMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$217K Sell
21,920
-4,830
-18% -$44.4K ﹤0.01% 5764
2026
Q2
$207K Buy
26,750
+4,100
+18% +$27.9K ﹤0.01% 5734
2026
Q1
$118K Buy
22,650
+2,076
+10% +$11.6K ﹤0.01% 5643
2025
Q4
$122K Buy
20,574
+4,899
+31% +$35.2K ﹤0.01% 5562
2025
Q3
$108K Buy
+15,675
New +$127K ﹤0.01% 5501
2024
Q2
– Sell
-41,000
Closed -$222K – 5119
2024
Q1
$222K Buy
+41,000
New +$294K ﹤0.01% 4432

Other funds holding SGMT

LPL Financial's SGMT Position: Q3 2026 in Review

LPL Financial reduced its Sagimet Biosciences (SGMT) stake by 18% in Q3 2026, selling an estimated $44.4K and leaving 21,920 shares worth $217K. The position accounts for ﹤0.01% of the portfolio, ranked #5764.

LPL Financial first reported a position in SGMT in Q1 2024 and has held it in 6 quarters since. The position peaked at $222K in Q1 2024. 153 funds tracked by Wall St. Rank hold SGMT as of Q3 2026.

  • LPL Financial held 21,920 shares of Sagimet Biosciences worth $217K as of Q3 2026.
  • LPL Financial sold 4,830 Sagimet Biosciences shares in Q3 2026, an estimated $44.4K.
  • Sagimet Biosciences made up ﹤0.01% of LPL Financial's portfolio in Q3 2026, its #5764 holding.
  • LPL Financial first reported a position in Sagimet Biosciences in Q1 2024 and has held it in 6 quarters since.
  • LPL Financial's Sagimet Biosciences position peaked at $222K in Q1 2024.
  • 153 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q3 2026.

Based on LPL Financial's 13F filing for Q3 2026, filed 6 Nov 2026.